You are here: Industry Insights > respiratory failure

News List

NeuroRx Announces ZYESAMI Trial Met Primary Endpoint americanpharmaceuticalreview
March 30, 2021
NeuroRx reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with ...
Zyesami™ shows promise in critical COVID-19 patients with respiratory failure europeanpharmaceuticalreview
February 26, 2021
Preliminary data indicate that Zyesami reduces the length of hospital stay in critical COVID-19 patients treated with High Flow Nasal Cannula (HFNC) therapy or mechanical ventilation.
NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19 prnewswire
February 10, 2021
NeuroRx, Inc. reported preliminary results from their Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) performed in collaboration with Relief Therapeutics Holdings, AG (SIX:RLF;OTCQB:RLFTF) in patients with respiratory failure due to ...
SGS Initiates COVID-19 Clinical Trials in U.S. contractpharma
December 01, 2020
Phase 2/3 trial will examine the safety, tolerability, and efficacy of Sarconeos (BIO101) to treat COVID-19 related respiratory failure.
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure prnewswire
November 16, 2020
NeuroRx, Inc. and Relief Therapeutics Holdings AG announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating respiratory failure in patients with..
NeuroRx, Relief Releases RLF-100 Data for COVID-19 Respiratory Failure americanpharmaceuticalreview
October 19, 2020
Relief Therapeutics and NeuroRx has announced topline results from 45 patients assessed in an open-label prospective study where 21 patients admitted to an intensive care unit (ICU) with critical COVID-19 and respiratory failure were treated with ...
NeuroRx Submits EUA Request for RLF-100 for COVID-19, Respiratory Failure americanpharmaceuticalreview
September 30, 2020
NeuroRx has submitted a request for an Emergency Use Authorization (EUA) with the FDA for the use of RLF-100™ aviptadil in patients who are receiving intensive care and who have exhausted all approved treatments.
Enlivex Announces First Patient Dosed in Allocetra Trial for COVID-19 with Respiratory Failure americanpharmaceuticalreview
August 13, 2020
Enlivex Therapeutics announced the first patient has been dosed in an investigator-initiated multi-center clinical trial of AllocetraTM in COVID-19 patients with severe illness and respiratory failures.
FDA Grants Inhaled Use IND for RLF-100 for COVID-19 to Prevent Respiratory Failure americanpharmaceuticalreview
August 12, 2020
NeuroRx and Relief Therapeutics announced NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.
RLF-100 Trial Shows Rapid Recovery from COVID-19 Respiratory Failure americanpharmaceuticalreview
August 10, 2020
NeuroRx and Relief Therapeutics announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19.

Previous page 1 2 Next page